Behavioral disturbances in Parkinson's disease patients receiving dopaminergic therapy

Cover Page

Cite item

Full Text


Introduction. Parkinson’s disease (PD) is a progressive neurological disorder caused by degeneration of dopaminergic neurons in the substantia nigra pars compacta. The most effective therapy for this disease includes dopaminergic drugs that may lead to the development of behavioral disturbances or impulse control disorders. The latter include compulsive buying, gambling addiction, hypersexuality, compulsive overeating, punding (nongoal oriented repetitive activity), and the dopamine dysregulation syndrome.

Objective. To reveal frequency of behavioral disturbances in patients with PD and assess their effect on quality-of-life parameters and activities of daily living in patients and their relatives.

Materials and methods. In order to determine the prevalence of impulse control disorders (ICD), 340 patients with PD were surveyed by completing the QUIPShort questionnaire to detect ICD. Sixty patients with PD with verified ICD (17% of the total number of patients examined) and 20 patients with PD without behavioral disturbances were included in further analysis; a number of specialized tests were used to assess ICD, impulsivity, activities of daily living, quality of life, anxiety, depression, and cognitive impairment.

Results. Dopamine dysregulation syndrome (DDS) was found in 8% of patients with PD; punding, in 10%; compulsive overeating, in 6%; hypersexuality, in 5%; compulsive buying, in 4%; and gambling addiction, in 1% of patients. The average parameter of activities of daily living for PD patients with ICD was 60.05 ± 9.76%; quality of life, 67.21 ± 18.54%. These values were significantly lower than those in patients without behavioral disturbances.

Conclusions. ICD is detected in every fifth patient with PD receiving dopaminergic therapy. DDS and punding are diagnosed most frequently. Development of ICD has a significant effect on patients’ activities of daily living and reduces quality of life both of the patients and their relatives.

About the authors

A. V. Nikitina

Russian Medical Academy of Postgraduate Continuing Education, Ministry of Healthcare of the Russian Federation

Russian Federation, Moscow

Natalia V. Fedorova

Russian Medical Academy of Postgraduate Continuing Education, Ministry of Healthcare of the Russian Federation

Author for correspondence.
Russian Federation, Moscow


  1. Golubev V.L., Levin Ya. I., Veyn A.M. Bolezn' Parkinsona i sindrom parkinsonizma.[Parkinson’s disease and parkinsonism]. Moscow. MEDpress-inform,1999. 415 p. (In Russ.)
  2. Litvinenko I.V. Bolezn' Parkinsona. [Parkinson’s disease]. Moscow. Miklosh,2010. 216 p. (In Russ.)
  3. Shtok V.N., Levin O.S., Fedorova N.V. Ekstrapiramidnye rasstroystva: [Extrapyramidaldisorders:]. Moscow. MIA, 2000. 175 p. (In Russ.).
  4. Evans A.H., Lawrence A.D., Potts J. et al. Factors influencing susceptibilityto compulsive dopaminergic drugs in Parkinson’s disease. Neurology; 2005: 65:1570–1574. PMID: 16301483. doi: 10.1212/01.wnl.0000184487.72289.f0.
  5. Evans A.H., Lees A.J. Dopamine dysregulation syndrome in Parkinson’s disease.Curr Opin Neurol. 2004; 17: 393–398. PMID: 15247533.
  6. Giovannoni G., O’Sullivan J.D., Turner K. et al. Hedonistic homeostatic dysregulationin patients with Parkinson’s disease on dopamine replacement therapies.J. Neurol. Neurosurg. Psychiatry. 2000; 68; 423–428. PMID: 10727476.doi: 10.1136/jnnp.68.4.423
  7. Lawrence A.J., Blackwell A.D., Barker R.A. et al. Prediction of punding inParkinson’s disease: result from a questionnaire survey. Mov. Disord. 2007; 22:2339–2345. PMID: 17914729. doi: 10.1002/mds.21702
  8. Voon V., Hassan K., Zurowski M. et al. Prevalence of repetitive and reward-seeking behaviors in Parkinson’s disease. Neurology. 2006; 67: 1254–1257.PMID: 16957130. doi: 10.1212/01.wnl.0000238503.20816.13.
  9. Weintraub D., Koester J., Potenza M.N. et al. Impulsive control disorders inParkinson’s disease: a cross-sectional study of 3090 patients. Arch. Neurol. 2010;67: 589–595. PMID: 20457959. doi: 10.1001/archneurol.2010.65
  10. Evans A.H., Katzenschlagen R., Pavior D. et al. Punding in Parkinson’s disease:its relation to the dopamine dysregulation syndrome. Mov Disord. 2004; 19:397–405. PMID: 15077237. doi: 10.1002/mds.20045.
  11. Lees A.J. The dopamine dysregulation syndrome. Mov Disord. 2008; 23:1332. doi: 10.1002/mds.22147.
  12. Lawrence A.D., Evans A.H., Lees A.J. Compulsive use of dopamine replacementtherapy in Patkinson’s disease: reward systems gone awry? Lancet Neurol.2003; 2: 595–604. PMID: 14505581 doi: 10.1016/S1474-4422(03)00529-5.
  13. Kirsch P., Schienle A., Stark R. et al. Anticipation of reward in a nonaversivedifferential conditioning paradigm and the brain reward system: an event-relatedfMRI study. Neuroimage. 2003; 20: 1086–1095. PMID: 14568478. doi: 10.1016/S1053-8119(03)00381-1.
  14. Evans A.H., Strafella A.P., Weintraub D., Stacy M. Impulsive compulsivebehaviors in Parkinson’s disease. Mov Disord. 2009; 24: 1561–1570. PMID: 19526584. doi: 10.1002/mds.22505.
  15. Cools R. Dopaminergic modulation of cognitive function-implications forL-DOPA treatment in Parkinson's disease. Neurosci Biobehav Rev. 2006; 30:1–23. PMID: 15935475. doi: 10.1016/j.neubiorev.2005.03.024.
  16. Weintraub D., Hoops S., Shea J.A. et al.Validation of the questionnaire forimpulsive-compulsive disorders in Parkinson’s disease. Mov. Disord. 2009; 24:1461–1467. PMID: 19452562. doi: 10.1002/mds.22571
  17. Hoehn M.M., Yahr M. Parkinsonism: onset, progression, and mortality.Neurology. 1967; 17: 427–442. PMID: 6067254.
  18. Fahn S., Elton R.L., and members of the UPDRS Development Committee.Unified Parkinson’s disease rating scale. In: Fahn S., Marsden C.D., Calne D.,Goldstein M., eds. Recent developments in Parkinson’s disease. Florham Park:Macmillan Healthcare Information, 1987: 153–163.
  19. Plutchik R., Van Praag H. The measurement of suicidality, aggresivity andimpulsivity. Prog. Neuropsychopharmacol. Biol. Psychiatry. 1989; 13: S23–S34.PMID: 2616792.
  20. Weintraub D.m Siderowf A.D., Potenza M.N. et al. Association of dopamineagonist use with impulsive control disorders in Parkinson’s disease.Arch Neurol. 2006: 63; 969–973. PMID: 16831966. doi: 10.1001/archneur.63.7.969.
  21. Diagnostic and Statistical Manual of Mental Disorders, Version IV (DSMIV).Washington, DC: American Psychiatric Association, 1994. 884 p.
  22. McElroy S.L., Keck P.E., Pope H.G. et al. Compulsive buying: a report of 20cases. J. Clin. Psychiatry. 1994; 55: 242–48. PMID: 8071278
  23. Herzog J., Valkmann J., Krack P. et al. Two-year follow-up of subthalamicdeep brain stimulation in Parkinson's disease. Mov. Disord. 2003; 18: 1332–1337.PMID: 14639676. doi: 10.1002/mds.10518.
  24. Pontone G., Williams J.R., Bassett S.S., Marsh L. Clinical features associatedwith impulse control disorders in Parkinson’s disease. Neurology. 2006; 67:1258–1261. PMID: 17030761. doi: 10.1212/01.wnl.0000238401.76928.45.
  25. Lee J.Y., Kim J.M., Kim J.W. et al. Association between the dose of dopaminergicmedication and the behavioral disturbances in Parkinson disease. ParkinsonismRelat. Disord. 2010; 16: 202–207. PMID: 20018549. doi: 10.1016/j.parkreldis.2009.12.002.

Supplementary files

Supplementary Files

Copyright (c) 2017 Nikitina A.V., Fedorova N.V.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77-83204 от 12.05.2022.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies